Transthyretin cardiac amyloidosis in internal medicine
Part of Brain & nervous system, Genetic & congenital, Hormones & metabolism clinical trials.
This study looks back at medical records of patients who were diagnosed with transthyretin cardiac amyloidosis (a type of protein buildup in the heart) while hospitalized in internal medicine at Strasbourg University Hospitals between 2013 and 2023. It aims to describe their health journey and outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older.
- You have been diagnosed with transthyretin cardiac amyloidosis (ATTR-CA).
- You were hospitalized in internal medicine at Strasbourg University Hospitals between 2013 and 2023.
- You do not have any other type of amyloidosis.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study collects information from people with a specific type of heart disease called cardiac amyloidosis (AL or ATTR type). By joining a registry, you help doctors learn more about these conditions and how to better treat them.
This study looks at how the liver and blood clotting are affected in people with a type of heart disease called transthyretin amyloidosis. It may help doctors better understand and manage this condition.
This is an observational study (no study drug) for people with transthyretin (TTR)–mediated amyloidosis, including people who carry certain gene changes before symptoms begin. It may help researchers better understand how the disease affects health over time and what to measure in future treatments.
This study looks at people who carry certain TTR gene variants, which can cause a specific type of heart amyloid buildup. It also includes people with symptoms, to understand how the condition develops and how it may be monitored.
This study looks at how a heart medication (tafamidis) affects amyloid protein levels in the blood over time. It may help doctors understand how well the treatment works for people with a specific type of heart disease caused by amyloid buildup (ATTR-CM).
This study follows patients with ATTR amyloidosis over time to understand how the disease affects them. It does not test a new treatment—instead, it asks you to fill out questionnaires about your health and symptoms to help doctors learn more about the condition.
Hear when a new Cardiac Amyloidosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.